Emily B. Bisen-Hersh

Learn More
OBJECTIVE With the survival rate of acute lymphoblastic leukemia (ALL) surpassing 90 percent within this decade, new research is emerging in the field of late effects. A review of the research investigating the relationship of treatment regimens for ALL to specific late effect deficits, underlying mechanisms, and possible remediation is warranted to support(More)
PURPOSE Among children diagnosed with acute lymphoblastic leukemia (ALL) and given chemotherapy-only treatment, 40% to 70% of survivors experience neurocognitive impairment. The present study used a preclinical mouse model to investigate the effects of early exposure to common ALL chemotherapeutics methotrexate (MTX) and cytarabine (Ara-C) on learning and(More)
Conflict of Interests: The authors have declared that no conflict of interest exists. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Acute lymphoblastic leukemia, the most common form of cancer in children and adolescence, has a survival rate of over 90%. Clinical studies estimate that among survivors(More)
Purpose: Among children diagnosed with acute lymphoblastic leukemia (ALL) and given chemotherapy-only treatment, 40% to 70% of survivors experience neurocognitive impairment. The present study used a preclinical mouse model to investigate the effects of early exposure to common ALL chemotherapeutics methotrexate (MTX) and cytarabine (Ara-C) on learning and(More)
  • 1